Amneal Pharmaceuticals (AMRX) announced that three large insurance coverage accounts, the Veterans Administration, UnitedHealthcare (UNH) and CVS Health (CVS), have added Crexont extended-release capsules for the treatment of Parkinson’s disease to their national prescription drug formularies. Crexont is a prescription medication for the treatment of PD approved by the FDA in August 2024. This expanded coverage increases Crexont’s total U.S. insurance coverage from about 30% of covered lives at the end of 2024 to over 50%.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals announces U.S. launch of Boruzu
- Amneal Pharmaceuticals (AMRX) Stock Soars 45% on Success of New Parkinson’s Treatment
- Amneal Pharmaceuticals BLA submissions for denosumab biosimilars accepted by FDA
- Amneal Pharmaceuticals price target raised to $11 from $10 at Barclays
- Amneal Pharmaceuticals Reports Strong 2024 Financial Results
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue